Search

Savara Inc

Nyitva

SzektorEgészségügy

5.6 0.18

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

5.51

Maximum

5.64

Fő mutatók

By Trading Economics

Bevétel

-2.9M

-40M

Egy részvényre jutó nyereség

-0.16

Munkavállalók

70

EBITDA

-3M

-40M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+99.46% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 10.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-32M

1.1B

Előző nyitás

5.42

Előző zárás

5.6

Hangulat hírek alapján

By Acuity

48%

52%

162 / 340 Rangsor szerint Healthcare

Savara Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 25. 19:16 UTC

Event

Savara Inc announced presentations at the ERS Congress, yet shares are trading lower today, reflecting a slight decline since Monday's close.

2026. aug. 24. 22:01 UTC

News

Savara Inc. will present Phase 3 trial results for molgramostim at the European Respiratory Society Congress in 2026. Shares are higher in after-market trading.

2026. aug. 21. 19:36 UTC

News

Savara Inc. granted inducement awards to eight new employees, including options for 74,500 shares. Shares are higher since Thursday's close.

2026. aug. 20. 20:02 UTC

Savara Inc shares are lower amid a broader market downturn, influenced by disappointing sales growth from major retailers like Walmart Inc. Trading volume remains unusually high.

2026. aug. 19. 19:26 UTC

Savara Inc is trading higher today, maintaining upward momentum since Tuesday's close. The stock moved from a session low to a pre-market high.

2026. aug. 18. 23:01 UTC

Savara Inc shares declined in after-market trading, falling below their 20-day moving average after an earlier surge. No specific news was identified to explain the volatility.

2026. aug. 17. 19:46 UTC

Savara Inc is trading lower today, retracing from earlier gains and near the lower end of its one-month range. No specific news was identified.

2026. aug. 14. 19:44 UTC

Savara Inc shares are higher today amid increased trading volume. No specific company news was identified to explain the price movement.

2026. aug. 13. 20:02 UTC

Savara Inc shares are lower today, continuing a decline since Wednesday. The stock saw high trading volume amid no specific news.

2026. aug. 12. 19:56 UTC

News

Savara Inc. shares are higher following Citizens' reaffirmation of its Outperform rating and $10 price target ahead of the MOLBREEVI PDUFA date.

2026. aug. 11. 19:11 UTC

Savara Inc shares are lower today amid unusually high market volume. No specific news was identified to explain the decline.

2026. aug. 10. 23:01 UTC

Savara Inc shares are lower in after-market trading, showing notable volatility without any specific news to explain the decline.

2026. aug. 7. 19:36 UTC

Savara Inc is trading higher, benefiting from broader market gains following a weaker-than-expected jobs report that may delay Federal Reserve interest rate hikes.

2026. aug. 6. 20:06 UTC

Savara Inc shares are higher today, recovering from earlier declines and trading above their 20-day moving average. No specific news was identified for the move.

2026. aug. 5. 19:36 UTC

News

Savara Inc. shares are higher as the company advances its Biologics License Application for molgramostim, with a key PDUFA date approaching.

2026. aug. 4. 23:01 UTC

Savara Inc shares are trading higher in after-market hours, showing significant volatility with no specific news identified to explain the price movement.

2026. aug. 3. 20:06 UTC

Savara Inc is declining today, diverging from recent higher closes. Broader market indices, including the S&P 500 and Nasdaq 100, are gaining.

2026. júl. 31. 20:06 UTC

Event

Savara Inc shares are lower despite the European Patent Office granting a patent for MOLBREEVI, effective through March 2041. The stock remains near its one-month low.

2026. júl. 30. 20:09 UTC

Event

Savara Inc shares rise after the European Patent Office grants a patent for MOLBREEVI, providing protection until March 2041.

2026. júl. 29. 19:47 UTC

Savara Inc's shares are lower, marking five consecutive sessions of decline. Broader market performance is mixed as traders await the Federal Reserve's interest rate decision.

2026. júl. 28. 19:16 UTC

Savara Inc. shares are lower today amid ongoing price weakness. Broader markets like the FTSE 100 and DAX are showing resilience despite this decline.

2026. júl. 27. 14:02 UTC

Savara Inc shares are higher during Monday's session, reaching their peak at 9:30 AM ET. No specific news was identified to explain the movement.

2026. júl. 24. 20:02 UTC

Savara Inc shares are lower today, continuing a decline since Thursday amid high market volume. Broader market sentiment is affected by recent oil price volatility.

2026. júl. 21. 17:41 UTC

Savara Inc. shares are advancing today amid strong trading volume. The broader market is also positive, led by gains in technology stocks.

2026. júl. 20. 20:06 UTC

Savara Inc shares are higher, continuing their advance from Friday's close. Broader market sentiment remains mixed amid ongoing geopolitical concerns.

Társak összehasonlítása

Árváltozás

Savara Inc Előrejelzés

Célár

By TipRanks

99.46% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 11.17 USD  99.46%

Magas 16 USD

Alacsony 9 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Savara Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

6

Vétel

0

Tartás

0

Eladás

Hangulat

By Acuity

162 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag feletti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat